Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lloyd Benjamin

Psychiatry Sacramento, CA Medical Doctor

NPI 1811970072 CMS profile 1041696

4250 Auburn Blvd, Sacramento, CA 95841

Open in the dashboard

General payments

$2,932

160 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lloyd Benjamin of Sacramento, CA is reported in the CMS Open Payments database as having received $2,932 across 160 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $872 44
2024 General $1,029 59
2023 General $669 37
2022 General $108 6
2020 General $61 3
2019 General $193 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lloyd Benjamin
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Lloyd Benjamin were reported at $872. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Lloyd Benjamin Psychiatry median Middle half National median
2019 $193 $184 $59–$605 $163
2020 $61 $119 $36–$372 $114
2021 $0 $143 $43–$576 $132
2022 $108 $153 $50–$590 $149
2023 $669 $170 $56–$651 $160
2024 $1,029 $179 $57–$673 $164
2025 $872 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $590 44 payments
  2. Janssen Pharmaceuticals, Inc $576 23 payments
  3. ITI, Inc. $449 24 payments
  4. Otsuka America Pharmaceutical, Inc. $344 21 payments
  5. Neurocrine Biosciences, Inc. $244 12 payments
  6. Alkermes, Inc. $224 11 payments
  7. Lundbeck LLC $176 9 payments
  8. Indivior Inc. $171 9 payments
  9. E.R. Squibb & Sons, L.L.C. $45 2 payments
  10. Vanda Pharmaceuticals Inc. $33 1 payment
  11. Other $80 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,778 158 payments
  2. Education $153 2 payments
Products named General payments · program years 2019–2025
  1. INVEGA SUSTENNA $556 22 payments
  2. UZEDY $323 25 payments
  3. CAPLYTA Psychiatry $265 15 payments
  4. INGREZZA $244 12 payments
  5. REXULTI $206 14 payments
  6. CAPLYTA Psychiatry $184 9 payments
  7. PERSERIS $171 9 payments
  8. ARISTADA Cns $164 8 payments
  9. ARISTADA Cns $164 8 payments
  10. ABILIFY ASIMTUFII $160 8 payments
  11. Other $1,219 67 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

639

Median for Psychiatry & Neurology: 100

Drug cost

$498,045

Median for Psychiatry & Neurology: $2,986

Branded share of claims

45.4%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 23 $187,178
Vraylar Cariprazine Hcl Brand 85 $123,605
Abilify Maintena Aripiprazole Brand 33 $91,383
Invega Sustenna Paliperidone Palmitate Brand 23 $80,097
Olanzapine Generic 38 $4,051
Clozapine Generic 24 $3,666
Methylphenidate Er (La) Methylphenidate Hcl Brand 11 $3,658
Divalproex Sodium Er Divalproex Sodium Brand 21 $895
Quetiapine Fumarate Generic 62 $881
Bupropion Xl Bupropion Hcl Brand 28 $515

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INVEGA SUSTENNA
  • Janssen Pharmaceuticals, Inc $257
$257 23 —
CAPLYTA
  • ITI, Inc. $164
$164 — —
REXULTI
  • Lundbeck LLC $60
  • Otsuka America Pharmaceutical, Inc. $29
$89 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $86
$86 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $84
$84 23 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

160 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record